Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge

被引:35
作者
Giannini, D
Bacci, E
Dente, FL
Di Franco, A
Vagaggini, B
Testi, R
Paggiaro, P
机构
[1] Osped Cisanello, I-56100 Pisa, Italy
[2] Univ Pisa, Cardiothorac Dept, Pisa, Italy
[3] Glaxo Wellcome Inc, Verona, Italy
关键词
allergen challenge; asthma; beta(2)-agonist; inhaled corticosteroids; salmeterol; tolerance;
D O I
10.1378/chest.115.3.629
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: One week of regular treatment with salmeterol can induce tolerance to the protective effect of a beta(2)-agonist on early airway response to allergen (EAR). The objective was to assess whether inhaled corticosteroids revert tolerance to salmeterol. Study design: The study had a randomized, double-blind, placebo-controlled design. Patients and methods: Twelve subjects with mild allergic asthma and positive result of specific bronchial provocation test (sBPT) to allergen underwent three sBPTs, separated by 1 week. sBPT was done in all subjects after a single dose (T-1) and after 1 week of regular treatment with inhaled salmeterol (50 mu g bid) (T-2) in order to induce tolerance. Subjects were then randomized to receive either the same dose of salmeterol + beclomethasone dipropionate (BDP, 500 mu g bid) (group 1, n = 6) or placebo + BDP (group 2, n = 6) for 1 week before sBPT (T-3). Results: After a single dose of salmeterol (T-1), all subjects were protected against EAR, whereas after 1 week of regular treatment, the protective effect of salmeterol was totally or partially lost (T-2). Maximum FEV1 percent fall (Max Delta FEV1%) after allergen inhalation was significantly higher at T-2 than at T-1. All subjects except one of group 1 were protected against EAR after salmeterol + BDP (T-3), and Max Delta FEV1% at T-3 (median, 12%; range, 4 to 6%) was significantly lower than T-2 (median, 22%; range, 12 to 43%; p < 0.05 by Wilcoxon test). Subjects of group 2 did not show any significant protection against EAR after placebo + BDP treatment (T-3) Max Delta FEV1% at T-2 (median, 31%; range, 9 to 40%) and T-3 (median, 31%; range, 3 to 42%; not significant). Conclusions: In conclusion, the addition of inhaled BDP partially restored the bronchoprotective effect of salmeterol on allergen challenge that was lost after 1 week of regular treatment with salmeterol alone. This ability of BDP in reverting tolerance cannot be ascribed to a direct effect of corticosteroids per se on allergen challenge in this group of asthmatics.
引用
收藏
页码:629 / 634
页数:6
相关论文
共 26 条
[1]   EVALUATION OF PHARMACOTHERAPY FOR EXERCISE-INDUCED ASTHMA [J].
ANDERSON, S ;
SEALE, JP ;
FERRIS, L ;
SCHOEFFEL, R ;
LINDSAY, DA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1979, 64 (06) :612-624
[2]   Salmeterol tachyphylaxis in steroid treated asthmatic subjects [J].
Booth, H ;
Bish, R ;
Walters, J ;
Whitehead, F ;
Walters, EH .
THORAX, 1996, 51 (11) :1100-1104
[3]  
BRITTON MG, 1992, EUR RESPIR J, V5, P1062
[4]   TERBUTALINE-INDUCED DESENSITIZATION OF HUMAN-LYMPHOCYTE BETA-2-ADRENOCEPTORS - ACCELERATED RESTORATION OF BETA-ADRENOCEPTOR RESPONSIVENESS BY PREDNISONE AND KETOTIFEN [J].
BRODDE, OE ;
BRINKMANN, M ;
SCHEMUTH, R ;
OHARA, N ;
DAUL, A .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (03) :1096-1101
[5]   LONG-TERM EFFECTS OF A LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST, SALMETEROL, ON AIRWAY HYPERRESPONSIVENESS IN PATIENTS WITH MILD ASTHMA [J].
CHEUNG, D ;
TIMMERS, MC ;
ZWINDERMAN, AH ;
BEL, EH ;
DIJKMAN, JH ;
STERK, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1198-1203
[6]   INTERACTION OF INHALED BETA(2) AGONIST AND INHALED CORTICOSTEROID ON AIRWAY RESPONSIVENESS TO ALLERGEN AND METHACHOLINE [J].
COCKCROFT, DW ;
SWYSTUN, VA ;
BHAGAT, R .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (05) :1485-1489
[7]   Functional antagonism: Tolerance produced by inhaled beta(2) agonists [J].
Cockcroft, DW ;
Swystun, VA .
THORAX, 1996, 51 (10) :1051-1056
[8]  
DAHL R, 1982, EUR J RESPIR DIS, V63, P167
[9]   INVITRO DESENSITIZATION OF BETA-ADRENERGIC RECEPTORS IN HUMAN-NEUTROPHILS - ATTENUATION BY CORTICOSTEROIDS [J].
DAVIES, AO ;
LEFKOWITZ, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (03) :565-571
[10]  
ELLULMICALLEF R, 1975, LANCET, V2, P1269